Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to speed up FSHD drug development

NCT ID NCT04038138

Ongoing Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is working to create better tools for measuring muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). Researchers will follow 100 adults with FSHD for up to 24 months, testing new ways to track disease progression. The goal is to make future clinical trials more efficient and reliable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could provide better ways to measure FSHD progression, making future drug trials faster and more reliable.
What could go wrong
This is an observational study, not a treatment trial. It focuses on measurement tools, so it won't directly improve patient health. Results may not apply to all FSHD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

facioscapulohumeral muscular dystrophy muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

Contacts and locations

Locations

  • CHRU de Lille

    Lille, Hauts-de-France, 59000, France

  • CHU de Nice

    Nice, Provence-Alpes-Côte d'Azur Region, 06000, France

  • Myology institute Association

    Paris, Île-de-France Region, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.